Background
primary breast cancer
PROLIFERATION, MALIGNANCIES, DISEASE, BREAST CANCER
The nuclear proliferation marker, Ki67, is measured in many malignancies including primary breast cancer[Short-term presurgical treatment of patients with primary breast cancer, particularly those with ER + disease, has become popular to gain insights into drug activity but also for identifying groups of patients who may be candidates for response-adapted therapy[In the large majority of primary ER + breast cancer, Ki67 is markedly suppressed by just 2-week endocrine therapy[Evidence to inform whether the gain in prognostic insights from measuring Ki67